Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

PURPOSE: Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC) who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant tumors. We investigated the efficacy of erlotinib alone or in combination with chemotherapy in patients with these characte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jänne, Pasi A., Wang, Xiaofei, Socinski, Mark A., Crawford, Jeffrey, Stinchcombe, Thomas E., Gu, Lin, Capelletti, Marzia, Edelman, Martin J., Villalona-Calero, Miguel A., Kratzke, Robert, Vokes, Everett E., Miller, Vincent A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397694/
https://ncbi.nlm.nih.gov/pubmed/22547605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.1315
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados